Skip to content
HowShorted

Protara Therapeutics, Inc. short interest in 2022

In 2022, Protara Therapeutics, Inc.'s disclosed short interest ran from 2.70% of shares outstanding on 14 Jan 2022 to 0.76% on 30 Dec 2022, a change of -1.94 percentage points. The year's high was 2.70% on 14 Jan 2022 and its low 0.70% on 15 Dec 2022, averaging 1.32% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.92 days on 28 Feb 2022. Full history: Protara Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Protara Therapeutics, Inc. in 2022

2022 in figures

Start of year
2.70% (14 Jan 2022)
End of year
0.76% (30 Dec 2022)
Change
-1.94 pp
High
2.70% (14 Jan 2022)
Low
0.70% (15 Dec 2022)
Average
1.32%
Highest days to cover
9.92 (28 Feb 2022)
SEC filings marked
8

Every report in 2022

Protara Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20222.70%5.47
31 Jan 20222.48%4.85
15 Feb 20222.22%5.79
28 Feb 20222.62%9.92
15 Mar 20221.82%7.0310-K filed, results (8-K)
31 Mar 20221.68%4.90
14 Apr 20221.42%6.42
29 Apr 20221.32%8.57
13 May 20221.34%3.6610-Q filed, results (8-K)
31 May 20221.41%5.79
15 Jun 20221.34%7.51
30 Jun 20220.91%1.44
15 Jul 20221.20%2.53
29 Jul 20220.81%5.78
15 Aug 20220.80%3.0310-Q filed, results (8-K)
31 Aug 20220.87%3.33
15 Sep 20221.00%1.46
30 Sep 20220.90%2.19
14 Oct 20220.75%3.84
31 Oct 20220.77%2.31
15 Nov 20220.83%1.6210-Q filed, results (8-K)
30 Nov 20221.02%6.33
15 Dec 20220.70%4.95
30 Dec 20220.76%3.16

See also: Protara Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.